Tissue Regenix Group's quarterly market cap
declined
from Dec. 2022 (£39.75 Mil) to Jun. 2023 (£35.88 Mil) but then
increased
from Jun. 2023 (£35.88 Mil) to Dec. 2023 (£36.70 Mil).
Tissue Regenix Group's annual market cap
increased
from Dec. 2021 (£37.63 Mil) to Dec. 2022 (£39.75 Mil) but then
declined
from Dec. 2022 (£39.75 Mil) to Dec. 2023 (£36.70 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Tissue Regenix Group's Enterprise Value for Today is £47.49 Mil.
Tissue Regenix Group Market Cap Historical Data
The historical data trend for Tissue Regenix Group's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Tissue Regenix Group's Market Cap
For the Biotechnology subindustry, Tissue Regenix Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tissue Regenix Group's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's Market Cap distribution charts can be found below:
* The bar in red indicates where Tissue Regenix Group's Market Cap falls into.
Tissue Regenix Group Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Tissue Regenix Group's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tissue Regenix Group (LSE:TRX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Tissue Regenix Group Market Cap Related Terms
Thank you for viewing the detailed overview of Tissue Regenix Group's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Tissue Regenix Group (LSE:TRX) Business Description
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:TRX has been successfully added to your 